| Literature DB >> 33066611 |
Aysegul Mutlu-Ingok1, Dilara Devecioglu2, Dilara Nur Dikmetas2, Funda Karbancioglu-Guler2, Esra Capanoglu2.
Abstract
The interest in using natural antimicrobials instead of chemical preservatives in food products has been increasing in recent years. In regard to this, essential oils-natural and liquid secondary plant metabolites-are gaining importance for their use in the protection of foods, since they are accepted as safe and healthy. Although research studies indicate that the antibacterial and antioxidant activities of essential oils (EOs) are more common compared to other biological activities, specific concerns have led scientists to investigate the areas that are still in need of research. To the best of our knowledge, there is no review paper in which antifungal and especially antimycotoxigenic effects are compiled. Further, the low stability of essential oils under environmental conditions such as temperature and light has forced scientists to develop and use recent approaches such as encapsulation, coating, use in edible films, etc. This review provides an overview of the current literature on essential oils mainly on antifungal and antimycotoxigenic but also their antibacterial and antioxidant activities. Additionally, the recent applications of EOs including encapsulation, edible coatings, and active packaging are outlined.Entities:
Keywords: antibacterial; antifungal; antimycotoxigenic; antioxidant; essential oils
Mesh:
Substances:
Year: 2020 PMID: 33066611 PMCID: PMC7587387 DOI: 10.3390/molecules25204711
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Overview of studies about antibacterial properties of essential oils.
| Essential Oil From | Bacterial Culture | Method | MIC 1 | Reference |
|---|---|---|---|---|
|
| Broth dilution | 4–42.67 µL/mL | [ | |
| Broth microdilution | 3.75 µL/mL | [ | ||
| Broth microdilution | 0.012–0.025 µL/mL | [ | ||
| Broth microdilution | 0.16–0.62 (%) | [ | ||
| Broth dilution | 12.5–200 µg/mL | [ | ||
| Microdilution broth | 2–4 mg/mL | [ | ||
| Microdilution broth | 0.12–0.25 mg/mL | [ | ||
| Broth dilution | 100–400 µg/mL | [ | ||
| Microdilution | 72.27–114.63 µL/mL | [ | ||
|
| Broth macrodilution | 1.25 µL/mL | [ | |
|
| Broth dilution | 0.06–7.25 µL/mL | [ | |
| Broth microdilution | 3.75–15 µL/mL | [ | ||
| Broth microdilution | 0.05 µL/mL | [ | ||
|
| Dilution | 6.25 µL/mL | [ | |
| Microdilution broth | 2–4 mg/mL | [ | ||
| Microdilution | 4.03–8.37 mg/mL | [ | ||
| Broth microdilution | 3.75–7.50 µL/mL | [ | ||
| Broth microdilution | 0.025 µL/mL | [ | ||
|
| Broth macrodilution | 1.25–10 µL/mL | [ | |
|
| Broth dilution | 1.33–42.67 µL/mL | [ | |
|
| Dilution | 125–250 µL/mL | [ | |
| Broth macrodilution | 0.6–1.2 mg/mL | [ | ||
| Microdilution | 0.55–17.6 mg/mL | [ | ||
| Microdilution broth | 2–4 mg/mL | [ | ||
|
| Dilution | 62.5 µL/mL | [ | |
|
| Broth microdilution | 0.25 to >2 mg/mL | [ | |
| Broth dilution | 0.016–1 µL/mL | [ | ||
| Broth dilution | 160–640 µg/mL | [ | ||
| Microdilution broth | 0.5–2 mg/mL | [ | ||
|
| Microdilution | 0.78–3.12 mg/mL | [ | |
| Microdilution | 81.64–124.47 µL/mL | [ | ||
|
| Broth microdilution | 0.5 to >2 mg/mL | [ | |
| Microdilution | 0.67–10.8 mg/mL | [ | ||
|
| Broth dilution | 0.5–85 µL/mL | [ | |
|
| Broth dilution | 1.56–60 µL/mL | [ | |
| Microdilution | 1.38–44.23 mg/mL | [ | ||
| Agar dilution | 2–4 mg/mL | [ | ||
| Microdilution broth | 0.5–1 mg/mL | [ | ||
| Microdilution | 0.21 mg/mL | [ | ||
| Dilution | 0.304 mg/mL | [ | ||
| Microdilution | 58.54–85.67 µL/mL | [ | ||
|
| Macrobroth dilution | 1–4.5 µL/mL | [ | |
|
| Dilution | 20 µg/mL | [ | |
|
| Dilution | 20 µg/mL | [ | |
|
| Broth dilution | 320–640 µg/mL | [ | |
|
| Broth dilution | 0.12–0.25 µL/mL | [ | |
| Microdilution broth | 1–4 mg/mL | [ | ||
|
| Dilution | 5–10 µg/mL | [ | |
| Microdilution | 0.15–9.85 mg/mL | [ |
1 MIC: minimum inhibition concentration.
Overview of studies about antifungal properties of essential oils.
| Essential Oil From | Fungal Culture | Method | MIC/Inhibition 1 | Reference |
|---|---|---|---|---|
|
| Macrodilution | 1.25–2.5 µL/mL | [ | |
| Vapor diffusion | 0.012–0.06 µg/mLair | [ | ||
| Broth macrodilution | 0.8–50 µg/mL | [ | ||
|
| Broth microdilution | 0.5–2 µg/mL | [ | |
| Agar dilution | 0.7–1.5 µL/mL | [ | ||
| Agar dilution | 1–3.6 µL/mL | [ | ||
|
| Agar overlay technique | 100% inhibiton at 500 ppm | [ | |
|
| Macrodilution | 0.625 μL /mL | [ | |
|
| Macrodilution | 0.078 μL /mL | [ | |
|
| Semisolid agar antifungal susceptibility technique | 60 μL /L | [ | |
| Disc diffusion | 100% inhibiton at 20 µL | [ | ||
| Gradient plate | 2 mg/mL | [ | ||
|
|
| Broth microdilution | 62.5 µg/mL | [ |
|
| Poisoned food technique | 100% inhibition at 50–100 µL/L | [ | |
|
| Inhibition zone method | 1.67, >5 µL/mL | [ | |
| Gradient plate | 0.062–0.125 mg/mL | [ | ||
|
| Broth microdilution | 625–1250 µg/mL | [ | |
| Microatmosphere | 100% inhibition at 500 µL/L | [ | ||
| Microdilution | 625 to >2500 µg/mL | [ | ||
| Microdilution | 625 to >2500 µg/mL | [ | ||
|
| Agar dilution | ≥1500 ppm | [ | |
| Microdilution | 312 to >2500 µg/mL | [ | ||
| Microdilution | 312 to >2500 µg/mL | [ | ||
|
| Macrodilution | 2.5 μL/mL | [ | |
| Broth dilution | 750–1000 ppm | [ | ||
| Broth microdilution | 1.5 mg/mL | [ | ||
|
| Broth microdilution | 1000–2000 μg/mL | [ | |
|
|
| Poisoned food technique | 0.6 μL /mL | [ |
|
| Disc diffusion | 80.9–91.4% inhibition at 10 µL | [ | |
|
| Broth dilution | 73.7 μg/mL | [ | |
| Gas diffusion | 15.625 µL/Lair | [ | ||
| Vapor phase | 96% inhibition at 500 µL/Lair | [ | ||
|
| Broth microdilution | 31.25 ppm | [ | |
|
| Inhibition zone method | 1.67, >5 µL/mL | [ | |
|
| Agar dilution | 0.6–6.7 µL/mL | [ | |
| Gradient plate | 1–2 mg/mL | [ | ||
| Poisoned food technique | 33–75% inhibition at 1000 µL/L | [ | ||
|
| Poisoned food technique | 7–8 µL/mL | [ | |
|
| Disc diffusion | 9–27% inhibition at 500 µL/L | [ | |
|
| Contact and volatile assay | 100% inhibition at 500 µL | [ | |
| Modified microdilution | 3.25–10 mg/mL | [ | ||
|
| Microdilution broth | 10 µg/mL | [ | |
|
| Agar disc diffusion | 1.5 to >2 µL/mL | [ | |
| Agar dilution | 2–6 mL/L | [ | ||
| Gradient plate method | 1–2 mg/mL | [ | ||
|
| Broth microdilution | 125 ppm | [ | |
| Broth microdilution | 0.5–4 µL/mL | [ | ||
| Microdilution | 0.5–10 µg/mL | [ | ||
| Poisoned food technique | 90–100% inhibition at 0.2% EO | [ | ||
|
|
| Modified semisolid agar antifungal susceptibility | 1–2 μL/mL | [ |
| Agar dilution | 4.5–9 µL/mL | [ | ||
|
|
| Broth dilution | 0.6–0.7 µL/mL | [ |
|
|
| Modified semisolid agar antifungal susceptibility | 0.3–5 μL/mL | [ |
|
|
| Poisoned food technique | 0.3 µL/mL | [ |
| Broth microdilution | 5000–10,000 µg/mL | [ | ||
|
| Poisoned food technique | 400–550 ppm | [ | |
|
| - 2 | 250 µL/L | [ | |
| Poisoned food technique | 350–650 ppm | [ | ||
| Poisoned food technique | 200–550 ppm | [ | ||
| Agar dilution | 0.8–5.1 µL/mL | [ | ||
| Gradient plate | 0.5–1 mg/mL | [ | ||
| Agar dilution | 0.8–1.4 g/L | [ | ||
| Agar dilution | 0.8–1.4 g/L | [ | ||
| Disc diffusion | 50% inhibition at 1122–1641 μL/L | [ | ||
| Disc diffusion | 93–100% inhibition at 20 μg/mL | [ | ||
| Broth macrodilution | 1 μL/mL | [ | ||
|
|
| Macrodilution | 500 µg/mL | [ |
|
| Microdilution | 1000 µg/mL | [ | |
|
| Volatile phase assay | 100% inhibition at 1.6 μg/mLair | [ | |
|
| Microdilution | 150 µg/mL | [ | |
|
| Microdilution | 1000 µg/mL | [ | |
| Broth microdilution | 2500–5000 µg/mL | [ | ||
|
| Broth macrodilution | 600–1200 µL/L | [ | |
| Disc diffusion | 4.4–15.3% inhibition at 500 µL/L | [ | ||
|
| Broth microdilution | 0.5–1 µg/mL | [ | |
|
| Contact assay | 100% inhibition at 200 µL/L | [ | |
| Gradient plate | 0.25 mg/mL | [ | ||
|
| Broth microdilution | 31.25 ppm | [ | |
| Microatmosphere method | 100% inhibition at 500 µL/L | [ | ||
| Agar dilution method | 25–50 µL/mL | [ | ||
|
| - | 1–2 µL/mL | [ | |
| Agar dilution | >4000 µL/L | [ | ||
|
| Disc diffusion | 77.7–91.2% inhibition at 500 µL/L | [ | |
|
| Broth microdilution | 1–4 µg/mL | [ | |
|
| Broth microdilution | 0.5–1 µg/mL | [ | |
|
| Agar dilution | <500 µL/L | [ | |
|
| Inhibition zone method | 2.33, >5 µL/mL | [ | |
|
| Agar dilution | <500–1000 µL/L | [ | |
| Agar dilution | <500–1000 µL/L | [ | ||
|
| Contact assay | 100% inhibition at 200 µL/L | [ | |
|
| Broth macrodilution | 0.32–2.5 µL/mL | [ | |
|
| Agar dilution | 0.8–2.3 µL/mL | [ | |
|
| Agar dilution | 2500 ppm | [ | |
| Broth microdilution | 312–625 µg/mL | [ | ||
| Macrodilution | 0.16–0.64 µL/mL | [ | ||
|
| Incorporation | 3000–4000 ppm | [ | |
|
| Microdilution | 1250–2500 μg/mL | [ |
1: The inhibition (%) was stated for studies in which the MIC value is not indicated, 2: It is not specified.
Overview of studies about the antimycotoxigenic properties of essential oils.
| Essential Oil From | EO Concentration | Mycotoxin | Mycotoxin Inhibition (%) | Method | Reference |
|---|---|---|---|---|---|
| 0.2–0.5 mg/mL | AF 1 B1 | 6.88–84.1 | LC-MS-MS, LOD 2: NI 3 | [ | |
| 0.1–0.3% | AF B1 | 49.4–99.6 | HPLC, LOD: 2 ng/g | [ | |
| 10–1000 µg/mL | AF B1 | 1.1–80 | HPLC, LOD: NI | [ | |
|
| 500 µl/Lair | AF B1 | 100 | TLC, LOD: NI | [ |
|
| 1000 µg/mL | AF B1 | 100 | TLC, LOD: NI | [ |
|
| 140 µg/ml | Fum B1 | 66.65 | ELISA | [ |
|
| 500 µg/g | DON 5 | 100 | HPLC, LOD: NI | [ |
|
| 210–280 µg/mL | Fum 7 B1 | 88–93.35 | ELISA, LOD: NI | [ |
|
| 50–75 µl/L | OTA 8 | 58–90 | HPLC, LOD: 1 ng/g | [ |
| 1–8 µL/mL | AF B1 | 31.6–100 | TLC-UV, LOD: NI | [ | |
| 100–200 µL/mL | DON | 8.08–13.74 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 13.23–16.87 | HPLC, LOD: 0.01 μg/mL | [ | |
| 100–200 µL/mL | DON | 41.55–46.92 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 79.79–89.29 | HPLC, LOD: 0.01 μg/mL | [ | |
| 1–8 µL/mL | AF B1 | 31.6–100 | TLC-UV, LOD: NI | [ | |
| 10–1000 µg/mL | AF B1 | 5.5–89.6 | HPLC, LOD: NI | [ | |
| 100–200 µg/mL | DON | 29.05–35.05 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 15.15–70.81 | HPLC, LOD: 0.01 μg/mL | [ | |
| 100–200 µL/mL | DON | 57.10–62.73 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 26.97–66.56 | HPLC, LOD: 0.01 μg/mL | [ | |
| 100–200 µL/mL | DON | 46.01–52.48 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 1.61–5.05 | HPLC, LOD: 0.01 μg/mL | [ | |
| 0.1–0.7% | AF B1 | 45.6–100 | HPLC, LOD: 2 ng/g | [ | |
| 0.1–0.5 µL/mL | AF B1 | 17.9–93.4 | TLC, LOD: NI | [ | |
| 17.9–294.9 µg/mL | Fum B1 | 33.05–99.11 | HPLC; LOD: 0.125 ng/L | [ | |
| 17.9–294.9 µg/mL | Fum B2 | 30–99.4 | HPLC; LOD: 0.125 ng/L | [ | |
| 100–200 µL/mL | DON | 59.95–72.18 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 80–87.27 | HPLC, LOD: 0.01 μg/mL | [ | |
| 100–200 µL/mL | DON | 37.47–37.70 | HPLC, LOD: NI | [ | |
| 100–200 µL/mL | ZEA | 38.48–41.01 | HPLC, LOD: 0.01 μg/mL | [ | |
|
| 0.1–0.2% | OTA | 80.92–97.32 | HPLC, LOD: 0.3 ng OTA/mL, LOQ: 0.5 ng OTA/mL | [ |
|
| 0.1% | OTA | 92.06 | HPLC, LOD: 0.3 ng OTA/mL, LOQ: 0.5 ng OTA/mL | [ |
| 2000–3000 µL/L | OTA | 18.1–100 | HPLC, LOD: 1 ng/g | [ | |
| 100 µL/mL | ZEA | 19.87–30.79 | HPLC, LOD: 0.01 μg/mL | [ | |
| 0.1–0.9 µL/mL | AF B1 | 9.28–100 | TLC, LOD: NI | [ | |
|
| 0.1–0.5 µL/mL | AF B1 | 36.7–100 | TLC, LOD: NI | [ |
|
| 0.1–0.2 µL/mL | AF B1 | 82.43–100 | Broth culture technique | [ |
| 1000–2000 µL/L | OTA | 1.6–100 | HPLC, LOD: 1 ng/g | [ | |
|
| 0.2–0.5 µL/mL | AF B1 | 15–84.6 | TLC | [ |
| 100–500 ppm | OTA | 26.08–100 | HPLC | [ | |
| 75–600 μg/mL | Fum B1 | 0–99.6 | HPLC, LOD: 0.125 ng/L | [ | |
| 75–600 μg/mL | Fum B1 | 0–99.6 | HPLC, LOD: 0.125 ng/L | [ | |
| 250–450 ppm | AF | 1.87–100 | TLC, LOD: NI | [ | |
| 100–250 µg/mL | AF B1 | 63.1–100 | HPLC, LOD: 0.5 ng/mL | [ | |
| 100 µL/mL | ZEA | 19.71–22.32 | HPLC, LOD: 0.01 μg/mL | [ | |
|
| 0.3–0.5% | OTA | 97.68–97.89 | HPLC, LOD: 0.3 ng OTA/mL, LOQ: 0.5 ng OTA/mL | [ |
| 1000–5000 µL/L | OTA | 64.6–100 | HPLC, LOD: 1 ng/g | [ | |
|
| 0.1 g/mL | AF B1 | 23.3 | HPLC, LOD: NI | [ |
| 10–1000 µg/mL | AF B1 | 22.1–100 | HPLC, LOD: NI | [ | |
|
| 150 µg/mL | AF B1 | 100 | HPLC, LOD: 333 ng/mL | [ |
| 100–200 ppm | Citrinin | 68.86–92.44 | HPLC (RP-HPLC) | [ |
1: Aflatoxin, 2: Limit of detection, 3: No information provided, 4: Limit of quantificatiom, 5: Deoxynivalenol, 6: Zearalenone, 7: Fumonisin, 8: Ochratoxin A.
Overview of studies about antioxidant properties of essential oils.
| Essential Oil From | Most Abundant Compounds 1 | Method | Results | Reference |
|---|---|---|---|---|
| Linalool (39.9%), E-anethol (31.5%), longifolene (4.9%), eugenol (4.8%), α-terpinyl acetate (3.1%) | DPPH | EC50 = 0.002–0.494 mg/mL | [ | |
| Menthol (45.4%), menthone (24.4%), iso-menthone (8.3%), menthyl acetate (6%), 1,8-cineole (5.5%) | DPPH | EC50 = 58.41–n.d. 2 mg/mL | [ | |
|
| Methyl chavicol (83.1%), limonene (3.4%), spathulenol (3.1%), caryophyllene oxide (3.1%), β-gurjunene (1.7%) | DPPH | 30.8–93.5% (1–10 mg/mL EO) | [ |
| Neral (27%), carvone (25.7%), limonene (20.6%), dill apiole (8%), | DPPH | IC50 = 3000 μg/mL | [ | |
| DPPH | IC50 = 65.4 μg/mL | [ | ||
|
| β-Thujone (41.9%), α-thujone (18.4%), camphor (13.2%), germacrene D (4.8%), 1,8-cineole (3.4%) | DPPH | IC50 = 5030 μg/mL | [ |
| Limonene (30-n.d.%), tritetracontane (12-n.d.%), 1-phenyl-1,2-propanedione (11.6-n.d.%), 1-hydroxy,1-phenyl-2-propanone (8.1–1.9%), | DPPH | 29.1–29.5% (23.5–23.6 μg AAE/kg of fresh khat sample) | [ | |
| Cinnamaldehyde (77.34%), | Phosphomolybdenum assay | 108.75 mg of EO/equivalent to 1 mg of vitamin C in terms of antioxidant power | [ | |
| Phosphomolybdenum assay | 111.46 mg TEs 6/g sample | [ | ||
| Cinnamaldehyde (68.2%), eugenol (9.57%), β-caryophyllene (7.21%), 1,2-benzenedicarboxylic acid, mono(2-ethylhexyl) ester (3.27%) | DPPH | 4.62–57.56% inhibition | [ | |
| ABTS | 89.74% inhibition | [ | ||
| ABTS | 41.57% inhibition | [ | ||
| ABTS | 11.64% inhibition | [ | ||
| ABTS | 74.71% inhibition | [ | ||
| ABTS | 40.71% inhibition | [ | ||
| α-Turmerone (42.6%), β-turmerone (16.0%), ar-turmerone (12.9%), α-phellandrene (6.5%), 1,8-cineole (3.2%) | ABTS | 0.54 mg/mL | [ | |
|
| Linalool (16.02%), | DPPH | IC50 = 122.62 µg/ml | [ |
|
| 1,8-Cineole (eucalyptol) (63.81%), α-pinene (16.06%), aromadendrene (3.68%), | DPPH | IC50 = 2.9 | [ |
|
| Limonene (68.51%), α-terpineol (8.6%), α-terpinyl acetate (6.07%), α-pinene (3.01%), terpinen-4-ol (1.61%) | DPPH | IC50 = 4.56 | [ |
| 1,8-Cineole (56%), α-terpinyl acetate (9%), 4-terpineol (5.2%), α-terpineol (4.7%), α-pinene (3.8%), linalool (3.8%) | DPPH | IC50 = 135 μg/mL | [ | |
|
| Terpinene-4-ol (31.11%), γ-terpinene (25.30%), α-terpinene (12.7%), 1,8-cineole (6.83%), | DPPH | EC50 = 48.35 μg/mL | [ |
| Pulegone (70.66%), neo-menthol (11.21%), menthone (2.63%), | DPPH | IC50 = 69.60 μg/mL | [ | |
|
| Carvone (37.26%), 1.8-cineole (11.82%), terpinen-4-ol (8.72%), limonene (5.27%), campher (4.31%) | DPPH | IC50 = 80.45 μg/mL | [ |
| DPPH | 82.1–92.1% | [ | ||
| Linalool (31.65%), estragole (17.37%), methyl | DPPH | IC50 = 11.23–55.15 mg/mL | [ | |
| ABTS | 0.163 mM Trolox/mg of essential oils | [ | ||
| ABTS | 0.210 mM Trolox/mg of essential oils | [ | ||
| ABTS | 0.206 mM Trolox/mg of essential oils | [ | ||
|
| Germacrene (11.46%), 1,8 cineol (10.29%), | DPPH | IC50 = 0.59 mg/mL | [ |
|
| Citronellol (25.07%), citronellyl formate (10.53%), geraniol (10.46%), buthyl anthranilate (5.94%), isomenthone (5.88%) | DPPH | IC50 = 14.62 mg/mL | [ |
|
| Anethole (59.47%), pseudoisoeugenol (20.15), | DPPH | IC50 = 6.81 µg/mL | [ |
| β-Caryophyllene (43.47%), caryophyllene oxide (14.64%), octadecanoic acid (5.26%), n-hexadecanoic acid (4.45%), humulene (3.86%) | DPPH | 11.24–64.46% inhibition | [ | |
| 4-Carene (31.74%), α-pinene (23.58%), D-limonene (8%), δ-3-carene (7.73%), camphene (4.13%) | FRAP | IC50 = 0.063 mg/mL | [ | |
|
| Germacrene D (26.7%), caryophyllene oxide (14.3%), (E)-caryophyllene (13.8%), spathulenol (11.3%), limonene (2.8%) | ABTS | 2.02 mmol TEs/g sample | [ |
| α-Copaene (21.96%), eucalyptol (15.05%), δ-cadinene (9.63%), β-selinene (7.73%), α-selinene (6.42%) | DPPH | 16.19–4.01% (50–100 mg/mL EO concentration) | [ | |
| Eugenol (72.46%), eugenyl acetate (4.18%), β-caryophyllene (3.73%), tau muurolol (2.83%), isoeugenol (2.12%) | DPPH | 29.36–77.28% inhibition | [ | |
| β-Thujone (84.43%), α-thujone (4.68%), eucalyptol (4.07%), thymol (0.67%), β-eudesmol (0.64%) |
DPPH | 13.59 µmol Trolox/g | [ | |
|
DPPH | 13.86 µmol Trolox/g | [ | ||
| Camphor (30.48%), borneol (14.8%), 1,8-cineole (10.8%), camphene (7.29%), bornyl acetate (5.53%) | DCFH-DA 7 | IC50 = 51 μg/mL | [ | |
| Thymol (51.22%), carvacrol (12.59%), γ-Terpinene (10.3%), trans-13-Octadecenoic acid (9.04%), linalool (2.29%) | DPPH | IC50 = 0.619 µg/mL | [ | |
| Thymol (70.12%), | DPPH | IC50 = 0.26 mg/mL | [ | |
| Carvacrol (27.8%), thymol (16.8%), carvacrol acetate (6.87%), phytol (6.8%), thymoquinone (5.4%) | DPPH | IC50 = 0.16 mg/mL | [ | |
| Thymol (25.78%), carvacrol (17.47%), thymoquinone (7.11%), eugenol (6.36%), β-pinene (6.31%) | DPPH | IC50 = 0.3 mg/mL | [ | |
|
| Carvacrol (46.23–39.14%), thymol (18.8–14.82%), thymol acetate (5.72–2.25%), eugenol (5.15-n.d.%), carvacrol acetate (4.92–1.21%) | Phosphomolybdate assay | 1.96–2.41 mg of AAE/g of dry weight | [ |
| Camphene (11.5%), β -phellandrene (10.7%), 1,8-cineole (10.4%), α-zingiberene (6.9%), borneol (6.4%) | DPPH | IC50 = 470 μg/mL | [ |
1 Five most abundant compounds (>1%), 2: not determined, 3: gallic acid equivalent, 4: quercetin equivalent, 5: hydrogen peroxide radical scavenging assay, 6: Trolox equivalents, 7: dichloro-dihydro-fluorescein diacetate assay.
Figure 1The chemical structures of major active compounds of essential oils (EOs) with antioxidant activity (in alphabetical order).